Bristol-myers Squibb Compnay

Arun Kumar Gupta

T G Murali Dhar

Jingwu Duan

Bin Jiang

Zhonghui Lu

Ananta Karmakar

Carolyn A Weigelt

William John Pitts

Bingwei Vera Yang

Gregory D Brown

TG Murali Dhar

There are described ROR&#x3b3; modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders.

ROR &#x3b3; modulators

Described are ROR&#x3b3; modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders. 

Carbocyclic sulfone ROR&#x3b3; modulators

Cyclohexyl sulfone ROR&#x3b3; modulators

Described are ROR&#x3b3; modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders. 

Heterocyclic sulfone ROR&#x3b3; modulators

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases. 

Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases

Growing community of inventors

Bengaluru, India

Arun Kumar Gupta